Vanda's eczema drug fails mid-stage study

March 4 (Reuters) - Vanda Pharmaceuticals Inc said its experimental atopic dermatitis drug failed a mid-stage study to treat chronic itching, sending its shares down 8.7 percent in after-hours trading.